TRVI Stock Summary and Trading Ideas (Trevi Therapeutics | NASDAQ:TRVI)

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Trevi Therapeutics trades on the NASDAQ stock market under the symbol TRVI.

As of April 24, 2026, TRVI stock price climbed to $14.41 with 848,074 million shares trading.

TRVI has a beta of 1.88, meaning it tends to be more sensitive to market movements. TRVI has a correlation of 0.19 to the broad based SPY ETF.

TRVI has a market cap of $2.05 billion. This is considered a Mid Cap stock.

In the last 3 years, TRVI traded as high as $16.12 and as low as $.97.

The top ETF exchange traded funds that TRVI belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.

TRVI has outperformed the market in the last year with a price return of +126.9% while the SPY ETF gained +31.9%. TRVI has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +44.2% and +9.2%, respectively, while the SPY returned +3.8% and +5.1%, respectively.

TRVI support price is $13.55 and resistance is $14.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRVI shares will trade within this expected range on the day.